Exploratory Study to Assess the Biological Activity of ZD6126 in Subjects with Newly Diagnosed Metastatic Renal Cell Carcinoma (Stage IV)
Study identifier:D2820C00018
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Recruitment on Hold
Official Title
-
Medical condition
Carcinoma, Renal Cell
Phase
Phase 2
Healthy volunteers
No
Study drug
ZD6126, Placebo
Sex
All
Actual Enrollment
-
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Aug 2003
Estimated Primary Completion Date: 01 Feb 2004
Estimated Study Completion Date: 01 Feb 2004
Study design
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Jan 2011 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
